Expertise in
8
conditions

Fabrice Bonnet

Rennes, FR 
Expertise in
8
conditions
Rennes, FR 

Overview

Fabrice Bonnet practices practicing medicine in Rennes, France.

Mr. Bonnet is highly rated in 8 conditions, according to our data. His clinical expertise encompasses HIV/AIDS, Type 2 Diabetes (T2D), Cryoglobulinemia, Hormone Replacement Therapy (HRT), and Oophorectomy.

He is actively involved in clinical research, co-authoring 360 peer reviewed articles and participating in 11 clinical trials.

Gender

Male

Locations

Rennes, France
Other Locations
Bordeaux, France
Tours, 37000, France
Paris, France
Villejuif, France
Saint-andre-la-cote, France
Talence, France
4 Rue Larrey, Angers, 49100, France
4 Rue De La Chine, UMRS-938, Chine, France
Thenon, 75020, France
Avenue Du M.L. Koenig, Reims, 51092, France
CHU
Rouen, France
Pointe À Pitre, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Risk of Morbidity, Mortality and Long-term Monitoring of Antiretroviral Treatment in People Living With HIV: The ANRS CO3 Aquitaine Cohort - AquiVIH-NA
Risk of Morbidity, Mortality and Long-term Monitoring of Antiretroviral Treatment in People Living With HIV: The ANRS CO3 Aquitaine Cohort - AquiVIH-NA
Enrollment Status: Active_not_recruiting
Publish Date: July 07, 2026
Impact of an Artificial Intelligence Platform on Inappropriate Medication Use in Older Adults
Impact of an Artificial Intelligence Platform on Inappropriate Medication Use in Older Adults
Enrollment Status: Terminated
Publish Date: June 24, 2026
Intervention Type: Device
Study Phase: Not Applicable
Anemil Trial : Phase I/II Clinical Trial Evaluating the Interest of Interleukine-2 for Patients With Active Warm Hemolytic Anemia Resistant to Conventional Treatment
Anemil Trial : Phase I/II Clinical Trial Evaluating the Interest of Interleukine-2 for Patients With Active Warm Hemolytic Anemia Resistant to Conventional Treatment
Enrollment Status: Terminated
Publish Date: May 22, 2026
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Intra-nodal Injection of Gentamicin for the Treatment of Suppurated Cat Scratch Disease's Lymphadenitis: A Randomized Controlled Study
Intra-nodal Injection of Gentamicin for the Treatment of Suppurated Cat Scratch Disease's Lymphadenitis: A Randomized Controlled Study
Enrollment Status: Completed
Publish Date: March 25, 2026
Intervention Type: Drug
Study Drug: Gentamicin
Study Phase: Phase 3
Aging With HIV and Neurocognitive Decline, a Follow-up Study
Aging With HIV and Neurocognitive Decline, a Follow-up Study
Enrollment Status: Completed
Publish Date: January 30, 2025
Intervention Type: Other
Study Phase: Not Applicable
A Phase IIIb, Open-label, Hybrid Type III Trial Evaluating Implementation Strategies for Long-acting Cabotegravir Plus Long-acting Rilpivirine Every Two Months in HIV-1 Infected, Virologically Suppressed Adults in Select European Healthcare Settings
A Phase IIIb, Open-label, Hybrid Type III Trial Evaluating Implementation Strategies for Long-acting Cabotegravir Plus Long-acting Rilpivirine Every Two Months in HIV-1 Infected, Virologically Suppressed Adults in Select European Healthcare Settings
Enrollment Status: Completed
Publish Date: April 05, 2024
Intervention Type: Drug, Other
Study Drug: Cabotegravir
Study Phase: Phase 3
A Phase III, Randomized, Multicenter, Open-label, Non-inferiority Study Evaluating the Efficacy, Safety and Tolerability of Switching to Dolutegravir/Lamivudine Fixed Dose Combination in HIV-1 Infected Adults Who Are Virologically Suppressed
A Phase III, Randomized, Multicenter, Open-label, Non-inferiority Study Evaluating the Efficacy, Safety and Tolerability of Switching to Dolutegravir/Lamivudine Fixed Dose Combination in HIV-1 Infected Adults Who Are Virologically Suppressed
Enrollment Status: Completed
Publish Date: October 19, 2023
Intervention Type: Drug
Study Drugs: Dolutegravir+Lamivudine, Current antiretroviral regimen
Study Phase: Phase 3
A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Dolutegravir Plus Lamivudine in HIV-1 Infected Adults Who Are Virologically Suppressed
A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Dolutegravir Plus Lamivudine in HIV-1 Infected Adults Who Are Virologically Suppressed
Enrollment Status: Completed
Publish Date: July 19, 2023
Intervention Type: Drug
Study Drugs: Dolutegravir+Lamivudine, Tenofovir alafenamide based regimen
Study Phase: Phase 3
Prevention of Symptomatic Venous Thromboembolism by Low Molecular Weight Heparin in Hospitalized Medical Patients Aged 70 Years and Older : a Randomized Placebo-Controlled Study The SYMPTOMS (SYstematic Elderly Medical Patients Thromboprophylaxis : Efficacy on Symptomatic OutcoMeS) Study
Prevention of Symptomatic Venous Thromboembolism by Low Molecular Weight Heparin in Hospitalized Medical Patients Aged 70 Years and Older : a Randomized Placebo-Controlled Study The SYMPTOMS (SYstematic Elderly Medical Patients Thromboprophylaxis : Efficacy on Symptomatic OutcoMeS) Study
Enrollment Status: Completed
Publish Date: July 05, 2022
Intervention Type: Drug
Study Drug: Enoxaparin
Study Phase: Phase 3
Incidence and Risk Factors for Infections in Patient Treated With Corticosteroids, Immunosuppressive Drugs or Biotherapy for Immunologic and Inflammatory Diseases
Incidence and Risk Factors for Infections in Patient Treated With Corticosteroids, Immunosuppressive Drugs or Biotherapy for Immunologic and Inflammatory Diseases
Enrollment Status: Completed
Publish Date: February 03, 2022
Intervention Type: Biological
View 9 Less Clinical Trials

358 Total Publications

Sex Hormone Influences on Cardiovascular Risk.
Sex Hormone Influences on Cardiovascular Risk.
Journal: The New England journal of medicine
Published: July 29, 2026

Frequently Asked Questions about Fabrice Bonnet

Is Fabrice Bonnet a top-rated expert for HIV/AIDS?

MediFind is an objective health platform that identifies experts based on real-world data. Fabrice Bonnet is classified as an Distinguished expert for HIV/AIDS, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Fabrice Bonnet participate in research or clinical trials?

Yes. Fabrice Bonnet has published 358 articles and abstracts on conditions like HIV/AIDS. You can view a list of Fabrice Bonnet's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Bonnet's expertise for a condition
ConditionClose
    View All 83 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile